<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Multiple Myeloma | Pathophysiology & Forecasting</title>
    <meta name="description"
        content="Scientific overview of Multiple Myeloma pathophysiology, epidemiology, and treatment landscapes. Access the interactive forecasting model.">
    <link rel="icon" type="image/png" href="favicon.png">
    <link rel="stylesheet" href="style.css">
    <style>
        .scientific-content {
            line-height: 1.8;
            color: var(--text-secondary);
        }

        .scientific-content h3 {
            color: var(--text-primary);
            margin-top: 2rem;
            margin-bottom: 1rem;
        }

        .scientific-content h2 {
            margin-bottom: 1.5rem;
        }

        .citation-box {
            background: rgba(255, 255, 255, 0.03);
            border-left: 3px solid var(--text-accent);
            padding: 1.5rem;
            margin-top: 3rem;
            border-radius: 0 8px 8px 0;
        }

        .citation-item {
            font-size: 0.9rem;
            margin-bottom: 0.8rem;
            font-family: var(--font-mono);
        }

        .cta-button {
            display: inline-block;
            background: linear-gradient(135deg, var(--text-accent), var(--text-bio));
            color: var(--bg-primary);
            font-weight: 700;
            padding: 1rem 2rem;
            border-radius: 8px;
            margin-top: 2rem;
            transition: all 0.3s ease;
            text-transform: uppercase;
            letter-spacing: 1px;
            box-shadow: 0 4px 20px rgba(56, 189, 248, 0.3);
        }

        .cta-button:hover {
            transform: translateY(-3px);
            box-shadow: 0 8px 30px rgba(52, 211, 153, 0.4);
            color: #000;
        }

        .back-link {
            display: inline-flex;
            align-items: center;
            gap: 0.5rem;
            margin-bottom: 2rem;
            color: var(--text-secondary);
            font-size: 0.9rem;
        }

        .back-link:hover {
            color: var(--text-accent);
        }
    </style>
</head>

<body>
    <div class="bg-gradient"></div>

    <main class="container">
        <section class="section visible" style="padding-top: 4rem;">
            <a href="index.html" class="back-link">
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                    <line x1="19" y1="12" x2="5" y2="12"></line>
                    <polyline points="12 19 5 12 12 5"></polyline>
                </svg>
                Back to Home
            </a>

            <h1 class="hero-title">Multiple <span class="text-accent">Myeloma</span></h1>
            <p class="hero-subtitle">Pathophysiology, Epidemiology, and Treatment Landscape</p>

            <a href="https://myeloma.streamlit.app" target="_blank" class="cta-button">
                Launch Forecasting Model ↗
            </a>

            <div class="glass-panel scientific-content" style="margin-top: 4rem;">
                <h2>Pathophysiology</h2>
                <p>
                    Multiple Myeloma (MM) is a cytogenetically heterogeneous plasma cell malignancy characterized by the
                    clonal proliferation of malignant plasma cells within the bone marrow microenvironment. These
                    malignant
                    cells typically secrete a monoclonal immunoglobulin protein (M-protein) or free light chains, which
                    serve
                    as key biomarkers for diagnosis and monitoring.
                </p>
                <p style="margin-top: 1rem;">
                    The pathophysiology involves a complex interplay between myeloma cells and the bone marrow stromal
                    cells,
                    mediated by cytokines such as IL-6, TNF-&alpha;, and RANKL. This interaction leads to the defining
                    clinical
                    features often summarized by the <strong>CRAB</strong> criteria:
                </p>
                <ul class="styled-list" style="margin-top: 1rem;">
                    <li><strong>C</strong>alcium elevation (Hypercalcemia) due to increased osteoclast activity.</li>
                    <li><strong>R</strong>enal insufficiency caused by light chain cast nephropathy.</li>
                    <li><strong>A</strong>nemia resulting from marrow infiltration and suppressed erythropoiesis.</li>
                    <li><strong>B</strong>one abnormalities, specifically lytic lesions and osteoporosis.</li>
                </ul>

                <h3>Epidemiology</h3>
                <p>
                    MM accounts for approximately 10% of all hematologic malignancies. The incidence increases
                    significantly
                    with age, with a median age at diagnosis of approximately 69 years. In the United States, the SEER
                    database reports an age-adjusted incidence rate of roughly 7.1 per 100,000 men and women per year.
                    Racial disparities are notable, with incidence rates being more than twofold higher in African
                    Americans
                    compared to White Americans.
                </p>

                <h3>Treatment Landscape</h3>
                <p>
                    The therapeutic landscape for myeloma has evolved rapidly. Standard of care has shifted from simple
                    alkylating agents to novel combination therapies targeting specific cellular mechanisms:
                </p>
                <ul class="styled-list" style="margin-top: 1rem;">
                    <li><strong>Proteasome Inhibitors (PIs):</strong> Bortezomib, Carfilzomib, Ixazomib. Disruption of
                        protein homeostasis in plasma cells.</li>
                    <li><strong>Immunomodulatory Drugs (IMiDs):</strong> Lenalidomide, Pomalidomide. Cereblon-mediated
                        degradation of Ikaros/Aiolos.</li>
                    <li><strong>Monoclonal Antibodies (mAbs):</strong> Daratumumab, Isatuximab (Anti-CD38); Elotuzumab
                        (Anti-SLAMF7).</li>
                    <li><strong>BCMA-Targeted Therapies:</strong> Chimeric Antigen Receptor (CAR) T-cell therapies and
                        Bispecific T-cell Engagers (BiTEs) representing the newest frontier in relapsed/refractory
                        settings.</li>
                </ul>
            </div>

            <div class="citation-box">
                <h4 style="color: var(--text-primary); margin-bottom: 1rem;">Scientific References & Resources</h4>
                <div class="citation-item">
                    1. Rajkumar, S. V., et al. (2014). "International Myeloma Working Group updated criteria for the
                    diagnosis of multiple myeloma." <em>The Lancet Oncology</em>.
                </div>
                <div class="citation-item">
                    2. Kumar, S. K., et al. (2020). "Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines
                    in Oncology." <em>Journal of the National Comprehensive Cancer Network</em>.
                </div>
                <div class="citation-item">
                    3. GBD 2016 Multiple Myeloma Collaborators. (2018). "Global, regional, and national burden of
                    multiple myeloma, 1990–2016." <em>JAMA Oncology</em>.
                </div>
                <div class="citation-item">
                    4. SEER Cancer Stat Facts: Myeloma. National Cancer Institute. <a
                        href="https://seer.cancer.gov/statfacts/html/mulmy.html" target="_blank"
                        style="color: var(--text-accent); text-decoration: underline;">seer.cancer.gov</a>
                </div>
            </div>

        </section>

        <footer class="footer section" style="margin-top: 0; border-top: none;">
            <p class="copyright">© 2026 Rushath Rajeev. All rights reserved.</p>
        </footer>
    </main>
</body>

</html>